# China Resources Biopharmaceutical CO.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/china-resources-biopharmaceutical-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.crbiopharm.com
- Total disclosed funding: $90M
- Latest round: Series B (Jan 10, 2023)
- Investors on record: 6

## About

Established in 2016 and based in Shenzhen, China, China Resources Biopharmaceutical CO., Ltd. is a biopharmaceutical company that engages in the R&D, production, and sales of biology medicals. It is a subsidiary of CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED. It has four subsidiaries in Shandong, Beijing, Shanghai, and Shenzhen. And it owns one production base and three R&D platforms. Moreover, it has approximately 400 employees. Its partners include Immvira Co., Ltd., AbStudio Inc., Pharmaron Beijing, and others. 

China Resources Biopharmaceutical CO., Ltd. provides biology drugs for oncology, cardiovascular, allergic diseases, and ophthalmology diseases, using the technologies of recombinant protein and antibodies. It has launched three drug pipelines, 24 drug pipelines in R&D phases, and six drug pipelines in clinical trials. The three drugs launched injection used recombinant human interleukin-11 for thrombocytopenia during chemotherapy, recombinant human tissue-type fibrinogen kinase derivative for acute myocardial infarction, and recombinant human erythropoietin injection for anemia.

## Funding rounds

- Series B, Jan 10, 2023, $90M — CCT Fund Management, CCB Private Equity Investment Management, Guangdong Technology Venture Capital, China Structural Reform Fund Co., Ltd., Wuxi Guolian Xinchuang private equity Investment Fund
- Series A, Dec 25, 2021 — Cowin Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- CCT Fund Management — Series B
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series B
- Guangdong Technology Venture Capital (https://capitalatlas.ai/funds/guangdong-technology-venture-capital) — Series B
- China Structural Reform Fund Co., Ltd. — Series B
- Wuxi Guolian Xinchuang private equity Investment Fund (https://capitalatlas.ai/funds/wuxi-guolian-xinchuang-private-equity-investment-fund) — Series B